Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines
- PMID: 34293462
- DOI: 10.1016/j.annonc.2021.07.004
Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines
Conflict of interest statement
Disclosure NC has received honoraria for lectures from AstraZeneca, Tesaro, Novartis, Clovis, Merck Sharp & Dohme, GlaxoSmithKline and Eisai; honoraria for advisory boards from Roche, PharmaMar, AstraZeneca, Merck Sharp & Dohme, Clovis Oncology, Tesaro, GlaxoSmithKline, Pfizer, OncXerna, BIOCAD, Immunogen, Mersana and Eisai; she has received research grant from AstraZeneca, PharmaMar and Roche. JAL has received honoraria for lectures and advisory boards from AstraZeneca, Tesaro Bio/GlaxoSmithKline and Eisai; honoraria for lectures from Clovis Oncology, for advisory boards from Artios Pharma, Merck Sharp & Dohme, Merck and Amgen; he has received compensation from Regeneron and institutional research grants from AstraZeneca Merck Sharp & Dohme and Merck; he has performed non-remunerated work in clinical trials for Merck Sharp and Dohme, Clovis Oncology, Pfizer, GlaxoSmithKline/Tesaro Bio and AstraZeneca.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
